0.00Open0.00Pre Close0 Volume0 Open Interest3.00Strike Price0.00Turnover1853.09%IV-73.38%PremiumJul 26, 2024Expiry Date8.27Intrinsic Value100Multiplier1DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type0.9559Delta0.0069Gamma1.30Leverage Ratio-0.3756Theta0.0001Rho1.24Eff Leverage0.0007Vega
Inovio Pharmaceuticals Stock Discussion
• BLA submission on track for INO-3107 in second half of 2024; if approved under accelerated approval pathway, could be first non-surgicaltreatment for recurrent respiratory papillomatosis (RRP)
• Planning initiation of confirmatory trial for INO-3107 based on FDA feedback
• Advancing plans for Phase 3 trial of INO-3112 in combination with LOQTORZITM ...
No comment yet